Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Philadelphia Chromosome 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Infections 1Hepatitis C 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 5Gemcitabine 4Albumin-Bound Paclitaxel 4Trastuzumab 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3pazopanib 2Taxes 2Sorafenib 2Radiotherapy 2Radiation 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Doxorubicin 2Docetaxel 2Capecitabine 2romidepsin 1rV-Tricom 1peginterferon alfa-2a 1pegfilgrastim 1oblimersen 1methyl N-acetylsibirosaminide 1ixabepilone 1fludarabine phosphate 1fludarabine 1exemestane 1cediranib 1alvocidib 1Zoledronic Acid 1Whole-Body Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms, Male × peginterferon alfa-2a × Clear all
NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡